Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 22, 2017. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs). It does not contain financial results, operational updates, or strategic commentary for the company as a whole.
Key Financial Metrics
The filing text does not provide company-level financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions by executives:
- Share Price: Transactions occurred at prices ranging from £16.3575 to £16.4750 per share.
- Transaction Volume: A total of 66,520 ordinary shares were exercised (nil-cost) and 31,282 shares were sold to meet tax liabilities across the three executives.
Material Changes
The filing does not report material changes to the company's business, financial condition, or results of operations compared to prior periods. The document solely discloses routine equity compensation events (exercise of options and subsequent sales for tax purposes) that occurred on February 21, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of insider trading activity compliant with the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Executive Activity: Three senior executives (Mr. R G Connor, Mr. S A Hussain, and Dr. P J T Vallance) exercised nil-cost options and sold shares on the same day.
- Transaction Nature: All sales were executed to meet tax liabilities arising from the exercise of options granted in February 2014 under the 2009 Deferred Annual Bonus Plan.
- Market Execution: Sales were conducted on the London Stock Exchange (XLON) at prevailing market prices.
- No Financial Data: Investors should not use this filing to assess GSK's financial performance; refer to the company's Form 20-F or quarterly reports for that data.